Heterocyclic Compounds And Their Uses As Inhibitors Of Pi3 K Activity

  • Published: May 5, 2011
  • Earliest Priority: Jun 25 2009
  • Family: 10
  • Cited Works: 0
  • Cited by: 0
  • Cites: 1
  • Additional Info: Full text
Abstract

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.


Claims

Information currently unavailable.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: May 5, 2011
  • Application: Jun 25, 2010
    WO US 2010/0039937 W
  • Priority: Jun 25, 2009
    US US 22049309 P

Download Citation


Sign in to the Lens

Feedback